Trial Profile
Intra-arterial Lutetium-177- dotatate for treatment of patients with neuroendocrine tumor liver metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms LUTIA LUTIA
- 23 Mar 2019 Planned number of patients changed from 25 to 26.
- 05 Jul 2018 New trial record